Medical News

RSS

FDA approves Xiaflex drug for treatment of Dupuytren's contracture

The U.S. Food and Drug Administration (FDA) has approved Xiaflex, a new drug to treat Dupuytren's contracture (or disease) that was discovered and developed by Marie A. Badalamente, Ph.D., and Lawrence C. Hurst, M.D., in the Department of Orthopaedics at Stony Brook University Medical Center.

4 Feb 2010

Acupuncture viable for treatment of depression during pregnancy

In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting -, in Chicago, researchers will unveil findings that show that acupuncture may be an effective treatment for depression during pregnancy.

4 Feb 2010

DNA variants in mother and fetus can increase risk of preterm labor

Researchers at the National Institutes of Health have identified DNA variants in mothers and fetuses that appear to increase the risk for preterm labor and delivery.

4 Feb 2010

HUCB-derived purified and expanded CD133+ cells may show promise in cellular cardiomyoplasty

Researchers at the Pontif-cia Universidade Cat-lica do Paran- and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence.

4 Feb 2010

UTMB: Mother's exposure to BPA increases risks of asthma in her children

For years, scientists have warned of the possible negative health effects of bisphenol A, a chemical used to make everything from plastic water bottles and food packaging to sunglasses and CDs.

4 Feb 2010

Study could lead to non-surgical alternatives for tonsillectomies

Children with obstructive sleep apnea (OSA) may one day be able to have an injection or use a throat spray instead of getting their tonsils removed to cure their snoring, according to a new study from the University of Chicago, which found that a specific gene product may be responsible for the proliferation of adenotonsillar tissue that can cause pediatric OSA.

4 Feb 2010

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma.

4 Feb 2010

Craft-kit therapy improves physical and mental health

Nearly 90 percent of HHV craft kit users report physical and mental improvements as a direct result of craft-kit therapy. Craft kits are an important rehabilitative tool used by the Department of Veterans Affairs (VA) to restore coordination and impaired motor skills, improve attention spans and concentration, and relax frayed nerves in patients.

4 Feb 2010

Study: Generic nifedipine product not bioequivalent to Adalat XL

An extended release generic nifedipine product (Mylan-Nifedipine extended release 60 mg formerly Gen-Nifedipine extended release 60mg, Genpharm ULC) is not bioequivalent to the Canadian originator product, Adalat(R) XL(R), according to the results of a study recently published in the International Journal of Clinical Pharmacology and Therapeutics.

4 Feb 2010

National consensus reached on Joint Technical Statement for drug products

A pan-Canadian initiative was announced today that will ultimately have a major impact on patient safety by reducing preventable medication errors.

4 Feb 2010

Canadian Institutes of Health Research awards $2.3M for study on integrative biology of inflammatory diseases

A research team led by Dr. John D. Rioux, a researcher at the Montreal Heart Institute (MHI) and professor in the faculty of medicine at the Université de Montréal, has been awarded a grant of more than $2.3 million to finance a major research project on the integrative biology of inflammatory diseases. From among the roughly 70 applications submitted, Dr. Rioux's team is one of six selected by the Canadian Institutes of Health Research to receive the Emerging Team Grant - From Genes to Proteins, Cells, Tissues and Patients.

4 Feb 2010

Organizations across Canada unite as partners to prevent chronic diseases among Canadians

More than 30 organizations from across Canada are uniting as partners in a series of initiatives designed to improve the health of Canadians by preventing chronic disease. A total of $15.5 million is being invested in seven collaborative coalitions addressing such issues as childhood obesity, screening for chronic disease by family doctors, and the unique needs of First Nations communities.

4 Feb 2010

GKAS volunteers provide free dental care for children

With an economy that might cause some parents to postpone regular dental visits for their children and tooth decay being the most prevalent chronic disease in America's children, the American Dental Association (ADA) is mobilizing dental professionals for the eighth consecutive year in a national campaign to extend necessary care to children and adolescents from low-income families.

4 Feb 2010

Geisinger Health System and TGen sign research agreement

Geisinger Health System and the Translational Genomics Research Institute today announced the signing of a strategic research agreement that provides a focused look at the gaps in clinical medicine where biomedical research can make a difference.

4 Feb 2010

Cardiac Science announces global voluntary recall of certain AEDs

Cardiac Science Corporation is initiating a worldwide voluntary recall after determining that approximately 12,200 automated external defibrillators (AEDs) may not be able to deliver therapy during a resuscitation attempt, which may lead to serious adverse events or death. These AEDs were manufactured in a way that makes them potentially susceptible to failure under certain conditions. The FDA has been informed of this situation.

4 Feb 2010

Prolactin reduces the levels of BCL6 protein and prevents aggressive breast cancer

Researchers from the Kimmel Cancer Center at Jefferson have found a mechanism by which a hormone responsible for milk production blocks an oncogene that makes breast cancer more aggressive.

4 Feb 2010

Fluorochemicals used in nonstick cookware and similar products to be phased out amidst toxic concerns

Amid concern about the potential toxic effects of the fluorochemicals used in nonstick cookware, water-repellent clothing, and other consumer products, manufacturers are using new versions of these chemicals that may be safer. That's the topic of the cover story in the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

4 Feb 2010

Despite improvements, aid delivery bottlenecks persist in Haiti

Three weeks after a major earthquake struck Haiti, challenges in getting aid to those in need persist, the Washington Post reports. "Rajiv Shah, the administrator of the U.S. Agency for International Development, said the relief effort has escalated in recent days and will continue to do so.

4 Feb 2010

MedQuist to acquire Spheris' domestic business

MedQuist Inc., a leading provider of medical transcription software and services, today announced that it has agreed to purchase the domestic business of Spheris Inc., a global provider of clinical documentation technology and services that recently filed for Chapter 11 bankruptcy protection.

4 Feb 2010

Recent clinical trials in patients with ALBP show that SOMA 250 mg reduces disability

A recent analysis of two pivotal clinical trials in patients with acute low back pain (ALBP) who were treated with SOMA® (carisoprodol) 250 mg showed significantly improved functionality and reduced disability after three days of treatment, as measured by the Roland-Morris Disability Questionnaire (RMDQ).

4 Feb 2010